Eloxatin
Gray-Zone Lymphoma
University of WashingtonPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Gray-Zone Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Polatuzumab Vedotin University of Washington | Phase 1 | CC |
Glofitamab University of Washington | Phase 1 | CC |
Obinutuzumab University of Washington | Phase 1 | CC |
Same molecule, other indications
Eloxatin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →